Vimentin DNA methylation predicts survival in breast cancer

Breast Cancer Research and Treatment

Volumn 137, Issue 2, 2013, Pages 383-396

  Ulirsch, Jacob ^a   Fan, Cheng ^a   Knafl, George ^a   Wu, Ming Jing ^a   Coleman, Brett ^a   Perou, Charles M ^a,b   Swift Scanlan, Theresa ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; DNA methylation; Epigenetic; Survival; Vimentin

Indexed keywords

MESSENGER RNA; TUMOR MARKER; VIMENTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; SURVIVAL PREDICTION; VIMENTIN GENE; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TUMOR CELL LINE;

BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; VIMENTIN;

MLCS; MLOWN;

EID: 84880582782     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2353-5     Document Type: Article

References (43)

1. Challa AA, Stefanovic B (2011) A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol Cell Biol 31:3773-3789. doi: 10.1128/MCB.05263-11
2. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124-1132. doi: 10.1093/jnci/dji204
3. Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ (2007) Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 35:e119. doi: 10.1093/nar/gkm662
4. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, Teixeira MR, Jeronimo C, Lind GE (2010) Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 16:5842-5851. doi: 10.1158/1078-0432.CCR-10-1312
5. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD (2008) Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 105:14867-14872. doi: 10.1073/pnas.0807146105
6. Ehrich M, Bocker S, van den Boom D (2005) Multiplexed discovery of sequence polymorphisms using base-specific cleavage and MALDI-TOF MS. Nucleic Acids Res 33:e38. doi: 10.1093/nar/gni038
7. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102:15785-15790. doi: 10.1073/pnas.0507816102
8. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, Wolff AC, Cope LM, Sukumar S (2011) Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71:6195-6207. doi: 10.1158/0008-5472.CAN-11-1630
9. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96. doi: 10.1186/1471-2164-7-96
10. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S, Shuber A (2007) Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 5:111-117. doi: 10.1016/j.cgh.2006.10.006
11. Ivaska J (2011) Vimentin: central hub in EMT induction? Small Gtpases 2:51-53. doi: 10.4161/sgtp.2.1.15114
12. Jung S, Yi L, Kim J, Jeong D, Oh T, Kim CH, Kim CJ, Shin J, An S, Lee MS (2011) The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol Cells 31:405-411. doi: 10.1007/s10059-011-0229-x
13. Katz E, Dubois-Marshall S, Sims AH, Gautier P, Caldwell H, Meehan RR, Harrison DJ (2011) An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS ONE 6:e17083. doi: 10.1371/journal.pone.0017083
14. Kisiel JB, Yab TC, Taylor WR, Chari ST, Petersen GM, Mahoney DW, Ahlquist DA (2011) Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer. doi: 10.1002/cncr.26558
15. Kitamura Y, Shirahata A, Sakuraba K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K (2011) Aberrant methylation of the Vimentin gene in hepatocellular carcinoma. Anticancer Res 31:1289-1291
16. Kitamura YH, Shirahata A, Sakata M, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K (2009) Frequent methylation of Vimentin in well-differentiated gastric carcinoma. Anticancer Res 29:2227-2229
17. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 185:191-203. doi: 10.1159/000101320
18. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271. doi: 10.1038/modpathol.3800528
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072. doi: 10.1200/JCO.2004.01.0454
20. Mendez MG, Kojima S, Goldman RD (2010) Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. The FASEB J 24:1838-1851. doi: 10.1096/fj.09-151639
21. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nat Cell Biol 5:59-63. doi: 10.1038/ncb898
22. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP (2006) Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25:2328-2338. doi: 10.1038/sj.onc.1209265
23. Ned RM, Melillo S, Marrone M (2011) Fecal DNA testing for colorectal cancer screening: the ColoSure test. PLoS Currents 3:RRN1220. doi: 10.1371/currents.RRN1220
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527. doi: 10.1016/j.ccr.2006.10.008
25. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K (2010) Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876-887. doi: 10.1158/1078-0432.CCR-09-1532
26. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167. doi: 10.1200/JCO.2008.18.1370
27. Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1):61-70. doi: 10.1634/theoncologist.2011-S1-61
28. Prat A, Ellis MJ, Perou CM (2012) Practical implications of gene-expression-based assays for breast oncologists. Nat Rev. Clin Oncol 9:48-57. doi: 10.1038/nrclinonc.2011.178
29. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68. doi: 10.1186/bcr2635
30. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, Herman JG, Baylin SB (2006) Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2:e40. doi: 10.1371/journal.pgen.0020040
31. Radpour R, Haghighi MM, Fan AX, Torbati PM, Hahn S, Holzgreve W, Zhong XY (2008) High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol Cancer Res 6:1702-1709. doi: 10.1158/1541-7786.MCR-08-0262
32. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY (2009) Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 28:2969-2978. doi: 10.1038/onc.2009.149
33. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J (2006) TM4 microarray software suite. Methods Enzymol 411:134-193. doi: 10.1016/S0076-6879(06)11009-5
34. Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM (2011) Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells. doi: 10.1002/stem.791
35. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989-997. doi: 10.1158/0008-5472.CAN-07- 2017
36. Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. doi: 10.1007/s00018-011-0735-1
37. Shirahata A, Sakata M, Sakuraba K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K (2009) Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res 29:279-281
38. Shirahata A, Sakuraba K, Goto T, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K (2010) Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients. Anticancer Res 30:5015-5018
39. Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, Dufloth R, Vieira D, Albergaria A, Veronese L, Carneiro V, Carvalho S, Costa JL, Zeferino L, Schmitt F (2010) P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol 25:963-974
40. Swift-Scanlan T, Vang R, Blackford A, Fackler MJ, Sukumar S (2011) Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 11:853-865. doi: 10.4161/cbt.11.10.15177
41. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY (2009) Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 27:549-560. doi: 10.1080/07357900802620794
42. Veeck J, Esteller M (2010) Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 15:5-17. doi: 10.1007/s10911-010-9165-1
43. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG (2007) hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 67:194-201. doi: 10.1158/0008-5472.Can-06-3396